Results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study were released at a session at the 9th South African AIDS Conference (SA AIDS 2019) in Durban, South Africa, on Thursday, June 13th. The session, which included presentations on the primary analysis, was recorded and can be viewed on YouTube here.
Similar Resources
End-user input is critical to inform development of multipurpose prevention technology (MPT) products that prevent HIV and pregnancy.
An essential first step in caring for HIV-infected children is accurate and early diagnosis of HIV, early HIV testing, prompt return of results, and rapid initiation of treatment.
DREAMS is an ambitious $385 million partnership to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries. The goal of DREAMS is to help girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe women.
Multipurpose prevention technologies (MPTs) are preferably single dosage forms designed to simultaneously address multiple sexual and reproductive health needs, such as unintended pregnancy, HIV infection and other sexually transmitted infections (STIs).
Many countries are working to reduce or eliminate mother-to-child transmission (MTCT) of HIV. Prevention efforts have been conceptualized as steps in a cascade but cascade completion rates during and after pregnancy are low.
A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection.
This photo story, about implementing the CHARISMA intervention pilot in Johannesburg, South Africa, illustrates how the pilot unfolded, starting with CHARISMA lay counselors conducting relationship assessments in 2016 with women using the vaginal dapivirine ring for HIV prevention in the MTN-025